Figure 4. Comparison of single cell, protein-based expression subtype assessment between primary and metastatic pancreatic tumors and patient-derived organoids.

A: Positivity for classical and basal subtype markers within individual cells in primary and metastatic specimens. All classical markers are more commonly expressed in cells from primary tumors and all basal markers are more commonly expressed in cells from metastatic tumors (Mann-Whitney test). B: Comparison of aggregate cell subtype fractions in primary and metastatic tumors (Chi² test). C: Co-expressor fraction among classical-predominant, mixed, and basal-predominant tumors. D: Tumor-level summary of tumor expression subtype and cell subtype fractions in metastatic PDAC (n=37). Top to bottom: tumor subtype using 2-group classification. Tumor subtype using 3-group classification. Cell subtype fraction per tumor. Co-expressor cell fraction per tumor. E: Tumor subtype distribution for primary and metastatic tumors (Chi² test). *** P<0.001, **** P<0.0001. F: Representative mIF images of classical-predominant and basal-predominant organoids. Scale bar = 50μm. G: Cell subtype fraction between primary tissue, metastatic tissue, primary organoid and metastatic organoid specimens. Both organoid cohorts exhibited significantly higher co-expressor cell fractions than the corresponding primary resection and metastatic biopsy tissue cohorts (Mann-Whitney test). H: Co-expressor cell abundance in primary tissue, metastatic tissue, primary organoid and metastatic organoid specimens (Mann-Whitney test). I: Co-expressor fraction among classical-predominant, mixed, and basal-predominant tumors for patient-derived organoids. Co-expressor cell fraction is higher in mixed tumors from primary and metastatic sites (4C), but not in patient-derived organoids (4I) (Mann-Whitney test). Statistical testing was not performed between basal and mixed tumors for organoids due to insufficient cases for comparison. *** P<0.001, **** P <0.0001.